The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2026 | Biomarkers and AI approaches to improve lung cancer screening accuracy
Maria Teresa Landi, MD, PhD, National Cancer Institute, Bethesda, MD, highlights the importance of identifying specific biomarkers for lung cancer screening, particularly in high-risk populations such as women and East Asian individuals between the ages of 50 to 74. Identifying aggressive and indolent tumors are needed to develop effective screening strategies, and genomics, cell of origin, epigenetics, and AI may play a crucial role in identifying sensitive biomarkers. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
